Floatz logo

ds-1594b

Recurrent Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer CenterPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

98 Active assets in the Recurrent Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Pevonedistat
Takeda
Phase 3BB
Venetoclax
Servier Bio-Innovation LLC
Phase 2/3BB
Azacitidine
The University of Hong Kong
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Astx727
Taiho Oncology, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

ds-1594b is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →